Current Clinical Trials

The Emphysema and COPD Research Center is participating in several clinical research studies investigating newer treatments for patients with COPD.
In addition, it maintains an active registry for patient participation in clinical research trials. The current research activities include:

Devices for Severe Emphysema/Hyperinflation

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 (BREATHE-3)

To evaluate safety and efficacy of Apreo BREATHE system in patients with severe emphysema and hyperinflation. It is a permanent implant designed to tent open native airways, and thus providing support to native airways and releasing trapped air from emphysematous blebs and bullae.

ClinicalTrials.gov Identifier: NCT06891755

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema (CONVERT-II)

To evaluate safety and effectiveness of the AeriSeal System (liquid sealant) for blocking collateral ventilation in patients with heterogeneous emphysema and air trapping who are ineligible for Zephyr valves due to incomplete fissures and the presence of collateral ventilation, as determined by incomplete major fissures on CT scan and per the Chartis Pulmonary Assessment System.

ClinicalTrials.gov Identifier: NCT06035120

Biologics and Novel Therapeutics

A Study to Evaluate Solrikitug in Participants With COPD

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Solrikitug (monoclonal antibody targeting TSLP) in patients with COPD (independent of exacerbation frequency) and elevated eosinophils. TSLP is a cytokine involved in initiating TH-2 inflammation and activation of downstream inflammatory cascades.

ClinicalTrials.gov Identifier: NCT06496620

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

To evaluate the efficacy and safety of Depemokimab in patients with COPD and frequent exacerbations and elevated eosinophils. It is an ultra-long-acting monoclonal antibody selectively binding to interleukin-5, with dosing every 6 months.

ClinicalTrials.gov Identifier: NCT06959095

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

To evaluate the efficacy and safety of AZD6793 (oral IRAK4 inhibitor) in patients with COPD and frequent exacerbations. It is a pill delivery which inhibits downstream pathways reducing both neutrophilic and eosinophilic inflammation.

ClinicalTrials.gov Identifier: NCT07082738

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

To evaluate efficacy and safety of two fixed dose inhaler combinations of ensifentrine (PDE3/4 inhibitor) and glycopyrrolate (long acting anticholinergic) vs ensifentrine monotherapy, glycopyrrolate monotherapy, or placebo in patients with COPD.

ClinicalTrials.gov Identifier: NCT07016412

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

To evaluate the effect of ensifentrine (nebulized PDE3/4 inhibitor) on sputum inflammatory biomarkers in patients with COPD.

ClinicalTrials.gov Identifier: NCT05270525